Detection of early precursors of t(12;21) positive pediatric acute lymphoblastic leukemia during follow-up.
DNA-, RNA-, and cell-based methods provide different biologic information for determining the presence of minimal residual disease (MRD). We monitored the responses of patients with pediatric acute lymphoblastic leukemia (pALL) using DNA markers, TEL/AML1 expression, and scanning fluorescence microscopy (SFM). Using SFM, 36% of patients exhibited 1.5-3.1 log and 2.9-4.2 log higher MRD levels compared with those based on DNA and RNA markers, respectively. CD10+ ancestor cells with germline antigen receptors, but silent TEL/AML1 expression, may reside in the lymphoid stem cell compartment of treated t(12;21)-positive patients and might act as a potential source of cells for late relapses.
László
Renáta
R
Department of Pathology, University of Pécs Medical Center, Pécs, Hungary. laszlo.pajor@kk.pte.hu
Alpár
Donát
D
Kajtár
Béla
B
Lacza
Agnes
A
Ottóffy
Gábor
G
Kiss
Csongor
C
Bartyik
Katalin
K
Nagy
Kálmán
K
Pajor
László
L
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002881:Chromosomes, Human, Pair 12 / Q000235:genetics*; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics*; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics; D004273:DNA, Neoplasm / Q000235:genetics; D005500:Follow-Up Studies; D006801:Humans; D018365:Neoplasm, Residual / Q000175:diagnosis* / Q000235:genetics* / Q000378:metabolism; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics; D014178:Translocation, Genetic; D000097764:ETS Translocation Variant 6 Protein
D050676:Core Binding Factor Alpha 2 Subunit; D004273:DNA, Neoplasm; D015514:Oncogene Proteins, Fusion; D012334:RNA, Neoplasm; C102421:TEL-AML1 fusion protein; D000097764:ETS Translocation Variant 6 Protein